Alpinia pricei Rhizome Extracts Induce Cell Cycle Arrest in Human Squamous Carcinoma KB Cells and Suppress Tumor Growth in Nude Mice by Hseu, You-Cheng et al.
Hindawi Publishing Corporation
Evidence-Based Complementaryand Alternative Medicine
Volume 2011, Article ID 123815, 11 pages
doi:10.1093/ecam/nep142
Original Article
Alpiniapricei RhizomeExtractsInduceCellCycle Arrestin
H u m a nSq u a m o u sC a r c i n o m aK BC e ll sa n dS u p p r e s sT u m o r
Growth in Nude Mice
You-ChengHseu,1 Chih-ShengChen,2 andSheng-YangWang3
1Department of Cosmeceutics, College of Pharmacy, China Medical University, 91 Huseh-Shih Road, Taichung 40402, Taiwan
2Institute of Nutrition, China Medical University, Taichung 40402, Taiwan
3Department of Forestry, National Chung Hsing University, Taichung 40402, Taiwan
Correspondence should be addressed to You-Cheng Hseu, ychseu@mail.cmu.edu.tw
Received 21 January 2009; Accepted 30 August 2009
Copyright © 2011 You-Cheng Hseu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Alpinia pricei has been shown to induce apoptosis in human squamous carcinoma (KB) cells. In this study, we report the
eﬀectiveness oftheethanol(70%)extracts ofA.pricei rhizome(APextracts) intermsoftumorregressionasdeterminedusingboth
in vitro cell culture and in vivo athymic nude mice models of KB cells. We found that the AP extract (25–200 μg/mL) treatment
decreased the proliferation of KB cells by arresting progression through the G2/M phase of the cell cycle. This cell cycle blockade
was associated with reductions in cyclin A and B1, Cdc2, and Cdc25C, and increased p21/WAF1, Wee1, p53 and phospho-p53
(p-p53) in a dose- and time-dependent manner. Moreover, we found that AP extract treatment decreased metalloproteinase-9
(MMP-9)andurokinaseplasminogenactivator(u-PA)expression,whileexpressionoftheirendogenousinhibitors,tissueinhibitor
ofMMP-1(TIMP-1)andplasminogenactivatorinhibitor-1(PAI-1),wereincreasedinKBcells.Furthermore, APextract treatment
eﬀectively delayed tumor incidence in nude mice inoculated with KB cells and reduced the tumor burden. AP extract treatment
also induced apoptotic DNA fragmentation, as detected by in situ TUNEL staining. Thus, A. pricei may possess antitumor activity
in humansquamous carcinoma (KB) cells.
1.Introduction
Alpinia pricei Hayata (family Zingiberaceae) is a perennial
rhizomatous herb indigenous to Taiwan. Rhizomes of the
Zingiberaceae family are vegetables widely used in many
Asian countries, and their medicinal functions are broadly
discussed and accepted in many traditional recipes. Alpinia
plants possess antioxidant [1], anti-inﬂammatory [2], anti-
cancer [3, 4], immunostimulatory [5], hepatoprotective [6]
andantinociceptive[7]activities. Furthermore,therhizomes
of Alpinia species (galanga) are used to treat problems asso-
ciated with the digestive system and to relieve symptoms
of bronchitis, measles, rubella and cholera [8]. Traditional
medicine in Algeria has used the roots of Alpinia species
for the treatment of respiratory infections for centuries [5].
Alpinia pricei is also used in traditional Chinese medicine to
treat abdominal distension and increase stomach secretion
and peristalsis [9, 10]; however, very few biological activity
tests are reported.
Chemoprevention, which refers to the administration of
naturally occurring agents to prevent initiation and promo-
tion events associated with carcinogenesis, is being increas-
ingly appreciated as an eﬀective approach for the man-
agement of neoplasia [11]. Many studies show associations
between abnormal cell cycle regulation and apoptosis and
cancer, in as much as the cell cycle inhibitors and apoptosis-
inducing agents are used for the management of cancer
[12]. Eukaryotic cell cycle progression involves the sequen-
tial activation of cyclin-dependent kinases (CDKs) whose
activation is dependent upon their association with cyclins
[13]. Progression through the mammalian mitotic cycle is
controlled by multiple holoenzymes comprising a catalytic
CDK and a cyclin regulatory subunit [13]. These cyclin-
CDK complexes are activated at speciﬁc intervals during2 Evidence-Based Complementary and Alternative Medicine
the cell cycle but can also be induced and regulated by
exogenous factors. Cell cycle progression is also regulated
by the relative balance between the cellular concentrations
of CDK inhibitors, including p27/KIP and p21/WAF1 [14].
The cyclin-CDK complexes are subjected to inhibition via
binding with CDK inhibitors [14].
Cancer metastasis, the spread of cancer cells from the
primary neoplasm to distant sites and their growth there, is
the major cause of death in various cancer patients [15]. Me-
tastasisofcancercellsinvolvesmultipleprocessesandvarious
cytophysiological changes, including changes in adhesion
capability between cells and extracellular matrix and abnor-
mal intercellular interaction. Thus, degradation of the extra-
cellular matrix and components of the basement membrane
caused by concerted action of proteinases, such as matrix
metalloproteinases (MMPs), cathepsins and plasminogen
activator (PA),playsa criticalrole intumorinvasion and me-
tastasis [16]. Among these enzymes, MMP-2, MMP-9 and
urokinase plasminogen activator(u-PA) candirectly degrade
most components of the ECM and are deeply involved
in cancer invasion and metastasis [17, 18]. Therefore, the
inhibition of migration or invasion mediated by MMP-2,
MMP-9 or u-PA could be a way to prevent or inhibit cancer
metastasis [17].
Cervical cancer, a slow growing squamous cell carci-
noma, is a common disease in women. Carcinoma of the
uterine cervix is one of the highest causes of mortality in
women cancer patients worldwide, and due to non-existent
or inadequate screening, the disease is normally detected in
thelatestage.For2000years, medicinalherbshavebeenused
in China to improve health and longevity. Studies utilizing a
variety of chemical or biological interventions demonstrated
promising results for induction of cell cycle arrest/apoptosis
and inhibition of metastasis in malignant cells. Previous
investigation demonstrated that ethanol (70%) AP extracts
exhibit antiproliferative eﬀects by induction of apoptosis
in human squamous carcinoma KB cells [19]. Thus, we
investigated the anticancer eﬀects of AP extracts (25–
200μg/mL) in terms of tumor regression using both in vitro
cell culture and in vivo athymic nude mice models of KB
cells. The levels of cell cycle/metastasis control and related
molecules were assayed to determine the A. pricei anticancer
mechanism.
2.Methods
2.1. Chemicals. Dulbecco’s Modiﬁed Eagle’s medium
(GIBCOBRL,Grand Island,NY),antibodyagainst cyclinB1,
Cdc2, p21/WAF1, Wee1, p53, phospho-p53 (p-p53), MMP-
9, u-PA, u-PA receptor (u-PAR), tissue inhibitor of MMP
(TIMP-1) and PAI-1 (Santa Cruz Biotechnology, Inc., Hei-
delberg, Germany), antibody against β-actin (Sigma
Chemical Co., St. Louis, MO), and antibody against cyclin
A, Cdc25C (Cell Signaling Technology Inc., Danvers, MA)
were obtained from their respective suppliers. All other
chemicals were of the highest grade commercially available
and supplied either by Merck (Darmstadt, Germany) or
Sigma.
2.2. Preparation of AP Extracts. The roots of A. pricei were
collectedinMarch2007inPing-tungCounty,anadministra-
tive region located in southern Taiwan, and were identiﬁed
by Dr Yen-Hsueh Tseng (National Chung Hsing University,
Taichung) [19]. The voucher specimen was deposited in the
herbarium of the same university. The air-dried roots (2kg)
of A. pricei were extracted with 10 l of 70% ethanol at room
temperature.Thecrudeextracts(166g)wereconcentratedin
a vacuum and freeze dried to form a powder. The stock was
thenstoredat −20◦Cforsubsequentanalysis ofitsanticancer
properties.The yieldofAPextractwas8.3%.Forpreparation
of the stock solution, the powder samples were dissolved in
70% ethanol at 25◦C.
2.3. Cell Culture and Assessment of Cell Growth and Viability.
The human carcinoma cell line, KB (HeLa derivative),
was obtained from the American type Culture Collection
(Rockville, MD). The KB cell line was used by the National
Cancer Institute, USA for some of the earliest in vitro anti-
cancer drug-screening work. They were originally thought
to be derived from an epidermoid carcinoma of the oral
cavity [20]. In fact, they were derived from a glandular
cancer of the cervix [21]. These cells were grown in DMEM
supplementedwith 10%heat-inactivated fetal bovine serum,
2 mM glutamine and 1% penicillin-streptomycin-neomycin
inahumidiﬁedincubator(5%CO2 inairat37◦C).Cellswere
seeded in 6- or 12-well plates prior to the addition of AP
extracts. The KB cells were incubated with AP extracts (0–
200μg/mL) for 24, 48 and 72h. Cultures were harvested and
monitored for cell number by counting cell suspensions in a
hemacytometer. Cell viability (3.0 × 105 cells/12-well dish)
and growth (1.0 × 105 cells/6-well dish) were checked before
and aftertreatment withAPextracts usingtrypan blueexclu-
sion and were examined using phase contrast microscopy.
2.4. Flow Cytometric Analysis. Cellular DNA content was
determined by ﬂow cytometric analysis of propidium iodide
(PI)-labeled cells [22]. KB cells were grown to exponential
phase, seeded at a density of 1 × 106 cells/60-mm dish, and
treated with the indicated concentrations of AP extracts (0–
200μg/mL) for 24 h. After treatment, the cells were collected
bytrypsinization,andﬁxedinice-cold70%ethanolat −20◦C
overnight. The cells were resuspended in phosphate buﬀered
saline (PBS) containing 1% Triton X-100, 0.5mg/mL of
RNase, and 4μg/mL ofPI at37◦Cf o r3 0m i n .AF A C S C a l i b u r
ﬂow cytometer (Becton Dickinson, San Jose, CA) equipped
with a single argon-ion laser (488nm) was used for ﬂow
cytometric analysis. Forward and right-angle light scatter,
which correlated with the size of the cell and the cytoplasmic
complexity, respectively, were used to establish size gates
and exclude cellular debris from the analysis. The DNA
content of 10000 cells per analysis was monitored using
the FACSCalibur system. The cell cycle was determined and
analyzed using ModFit software (Verity Software House,
Topsham, ME).
2.5. Preparation of Total Cell Extract and Immunoblot Anal-
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washed once in cold PBS, and then suspended in 100μL
lysis buﬀer (10mM T ris–HCl (pH 8), 0.32M sucrose, 1%
Triton X-100, 5mM EDTA, 2 mM dithiothreitol and 1mM
phenylmethyl sulfonyl ﬂuoride). The suspension was put
on ice for 20min and then centrifuged at 5000rpm for
20min at 4◦C. Total protein content was determined using
Bio-Rad protein assay reagent, with bovine serum albumin
as the standard; protein extracts were reconstituted in
sample buﬀer (0.062M Tris-HCl, 2% sodium dodecylsulfate
(SDS), 10% glycerol and 5%β-mercaptoethanol), and the
mixture was boiled for 5min. Equal amounts (50μg) of the
denatured proteins were loaded into each lane, separated on
8–15% SDS polyacrylamide gels, followed by transfer of the
proteins to polyvinylidene diﬂuoride (PVDF) membranes
overnight. Membranes were blocked with 0.1% Tween-20
in PBS containing 5% non-fat dried milk for 20min at
room temperature, and the membranes were reacted with
primary antibodies for 2h. They were then incubated with
either a horseradish peroxidase-conjugated goat anti-rabbit
or anti-mouse antibody for 2 h before being developedusing
SuperSignal ULTRA chemiluminescence substrate (Pierce,
Rockford,IL). Band intensities were quantiﬁed by densitom-
etry, with absorbance of the mixture at 540nm determined
using an enzyme-linked immunosorbent assay (ELISA)plate
reader. Western blot analyses, with antibodies against cyclin
A, cyclin B1, Cdc2, Cdc25C, p21/WAF1, Weel, p53, p-p53,
MMP-9, u-PA, u-PAR, TIMP-1 and PAI-1 were performed as
described previously [22].
2.6. Determination of MMP-9 by Zymography. The activi-
ties of MMP-9 in the medium were measured by gelatin
zymography protease assays [16, 17]. Brieﬂy, collected media
of an appropriate volume (adjusted by vital cell number)
were prepared with SDS sample buﬀer without boiling or
reductionandweresubjectedto0.1%gelatin–8%SDS-PAGE
electrophoresis. After electrophoresis, gels were washed with
2.5% Triton X-100 and then incubated in a reaction buﬀer
(40mM Tris-HCl, pH 8.0; 10mM CaCl2 and 0.01% NaN3)
at 37◦C for 12 h. Then, the gels were stained with Coomassie
brilliant blue R-250.
2.7. Animals. Female athymic nude mice (BALB/c-nu), 5–7
weeks of age, were purchased from GlycoNex, Inc., Taiwan,
and were maintained in caged housing in a speciﬁcally
designed pathogen-free isolation facility with a 12/12h
light/dark cycle; the mice were provided rodent chow and
water ad libitum. All experiments were conducted in accor-
dance with the guidelines of the China Medical University
Animal Ethics Research Board.
2.8. Tumor Cell Inoculation. KB cells (1 × 106 cells) were
mixed in a 200μL matrix gel and then injected subcuta-
neously on the right hind ﬂank. The components of matrix
gel includegrowth factors. These cells were grown in DMEM
medium supplemented with 10% heat-inactivated fetal
bovineserum,2mMglutamine,1%penicillin-streptomycin-
neomycininahumidiﬁedincubator(5%CO2 inairat37◦C).
Experiments were performed using cells from fewer than
20 passages. Tumor volume, as determined by caliper mea-
surements oftumorlength, widthand depth,were calculated
using the formula: length × width2× 1/2 every 3 days [23].
The two groups received intraperitoneal injections of AP
extracts (0.2mL/mouse) dissolved in PBS buﬀer at a dose of
10mg/kg every 2 days, while the control group received daily
injections of vehicle only. Following 27 days of treatment,
the mice were sacriﬁced. The tumors were removed before
ﬁxing in 4% paraformaldehyde, sectioning and staining with
hematoxylin-eosin for light microscopy. Part of the tumor
tissue was immediately frozen and the rest was ﬁxed in
10%neutral-buﬀeredformalin andembeddedinparaﬃn.To
monitor drug toxicity, the body weight of each animal was
measured every 3 days. In addition, a pathologist examined
the mouse organs, including liver, lungs and kidneys.
2.9. In Situ Apoptosis Detection. Apoptotic cell death in de-
parafﬁnized tissue sections was detected using terminal
deoxynucleotidyl transferase-mediated dUTP nick end-la-
beling(TUNEL)withtheKlenowDNAfragmentationdetec-
tion kit (Calbiochem, San Diego, CA) [24]. Brieﬂy, sections
were permeabilized with 20μg/mL protease K in Tris-
buﬀered saline, and endogenous peroxidase was inactivated
by 3% H2O2 in methanol. Apoptosiswasdetectedbylabeling
the 3 -OH ends of the fragmented DNA with biotin-dNTP
using the Klenow at 37◦C for 1.5 h. The slides were then
incubated with streptavidin horseradish peroxidase conju-
gate, followed by incubation with 3,3 -diaminobenzidine
and H2O2. Apoptoticcells were identiﬁed by the dark brown
nuclei observed with light microscopy.
2.10. Statistical Analyses. In vitro results are presented as
mean ± standard deviation (SD). For in vivo experiments,
mean data values are presented with standard error (SE). All
study data were analyzed using analysis of variance, followed
by Dunnett’s test for pair-wise comparison. Statistical signif-
icance was deﬁned as P < .05 for all tests.
3.Results
This study investigated the anticancer eﬀects of ethanol
(70%) extracts of A. pricei rhizomes both in vitro and in vivo
using the KB epidermoid carcinoma cell line and nude mice
xenograft models.
3.1. G2/M Arrest in AP Extracts-Treated KB Cells. The proﬁle
of the DNA content of the AP extract-treated KB cells (0–
200μg/mL for 24h) was obtained using ﬂow cytometric
analysis to measure the ﬂuorescence of PI-DNA binding.
The stage at which AP extract-induced growth inhibition
occurred in KB cell cycle progression was determined, along
with cellular distributions in the diﬀerent phases after treat-
ment. Figures 1(a) and 1(b) show that AP extract exposure
resulted in progressive and sustained accumulationofcellsin
the G2/M phase in a dose-dependent manner. Furthermore,
t h ep e r c e n t a g eo fSa n dG 2 / Mp h a s ec e l l si n c r e a s e d ,w h i l e
those in the G1 phase decreased after treatment with AP
extracts (Figures 1(a) and 1(b)). Our ﬁndings suggest that4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of A. pricei (AP) extracts on KB cell cycle distri-
bution. (a) Cells were treated with 0, 25, 50, 100, 150 or 200μg/mL
of AP extracts for 24 h, stained with PI, and analyzed for cell cycle
phase using ﬂow cytometry. (b) Cellular distribution (percentage)
indiﬀerentphasesofthecellcycle(G1,SandG2/M)afterAPextract
treatment. Results are presented as mean ± SD of three assays.
∗Signiﬁcant diﬀerence in comparison to control group (P < .05).
A. pricei promotes cell growth inhibition by inducing G2/M
phase arrest in cancer cells.
3.2. Western Blot Analysis of Cyclin A, Cyclin B1, Cdc2 and
Cdc25C Levels in KB Cells after Exposure to AP Extracts. In
order to examine the molecular mechanism(s) and under-
lying changes in cell cycle patterns, we investigated the
eﬀects of various cyclins and CDKs involved in cell cycle
control of KB cells. We approached this study by treating KB
cells with AP extracts (0–200μg/mL) for 0–24 h. Dose- and
time-dependent reductions in mitotic cyclins A and B1,
mitotic-cyclin dependent kinase Cdc2, and mitotic phos-
phatase Cdc25C expression with treatment were observed
(Figures 2(a) and 2(b)). This result implies that AP extracts
inhibited cell cycle progression by reducing cyclin A, cyclin
B1, Cdc2 and Cdc25C.
3.3. AP Extracts Increase the Expression of p21/WAF1, Wee1,
p53 and p-p53. A ss h o w ni no u rs t u d y ,A Pe x t r a c tt r e a t m e n t
of KB cells resulted in cell cycle arrest. Thus, we also
examined the eﬀect of exposure on cell cycle-regulatory
molecules, including p21/WAF1 (CDK inhibitors), Weel
(CDK relative factors), p53 and p-p53. Figures 3(a) and
3(b) show that treatment of KB cells with AP extracts (0–
200μg/mL for 0–24 h) induced marked dose and time-
dependentup-regulation ofp21/WAF1,Weel, p-p53 and p53
protein expression.
3.4. Eﬀects of AP Extracts on Levels of MMP-9, u-PA, u-
PAR, TIMP-1 and PAI-1, and on Activity of MMP-9. We also
investigated whether AP extracts inhibited metastasis-related
proteins in KB cells. We used western blotting to analyze
the eﬀects of AP extracts on MMP-9, u-PA, u-PAR, TIMPs
and PAI-1 expression. As shown in Figure 4,t r e a t m e n to f
KB cells with AP extracts (0–200μg/mL for 0–24h) induced
marked dose- and time-dependent reductions in MMP-9
and u-PA protein expression. Dose- and time-dependent
up-regulation of the speciﬁc endogenous inhibitors, TIMP-
1 and PAI-1 expression with AP extract treatment were
observed (Figures 4(a) and 4(b)). However, the experimen-
tal treatment did not appear to change the amount of
detectable u-PAR (u-PA receptor) protein (Figures 4(a) and
4(b)). Moreover, gelatin zymography assays showed that AP
extracts (0–200μg/mL for 24h) reduced MMP-9 activity in a
dose-dependent manner in KB cells (Figure 5).
3.5. In Vivo Inhibition of KB Xenograft Proliferation by AP
Extracts. Nude mice were used to evaluate the in vivo eﬀects
of AP extracts on tumor growth. KB cells were xenografted
into nude mice as described in “Methods” section. All
of the animals appeared healthy, with no loss of body
weight noted during AP extract treatment (Figure 6(a)). In
addition, no signs of toxicity were observed (body weight
and microscopic examination of individual organs; data not
shown) in any of the nude mice. The time course for KB
xenograft growth with AP extracts (10mg/kg/every 2 days)
or without treatment (control) is shown in Figures 6(b) and
7(a). Tumor volume in the AP extracts-treated mice was
inhibited as compared with the control group (Figure 7(a)).
Evaluation of tumor volume showed signiﬁcant dose-
and time-dependent growth inhibition associated with AP
extract treatment (Figure 6(b)). At the end of 27 days, the
KB xenograft tumor was excised from each sacriﬁced ani-
mal. Additionally, microscopic examination of the tumor
sections was done to distinguish diﬀerences in nucleic and
cytoplasmic morphology after the 27 days of AP extract
treatment. Furthermore, abundant mitosis was observed inEvidence-Based Complementary and Alternative Medicine 5
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Figure 2:Western blotanalysisofcyclinA,cyclin B1,Cdc2 andCdc25C protein levelsin KB cells afterexposure toAP extracts. (a)Cells were
treated with 0, 25, 50, 100, 150 or 200 μg/mL of AP extracts for 24h. (b) Cells were treated with 150μg/ml of AP extracts for 0, 4, 8, 12, 18
or 24 h. Protein (50μg) from each sample was resolved on 8–12% SDS–PAGE and western blotting was performed. β- a c t i nw a su s e da sa
control. Relative changes in protein bands were measured using densitometric analysis.Typical results from three independent experiments
are shown.
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Figure 3: Western blot analyses of p21/WAF1, Weel, p53 and p-p53 protein levels in KB cells after exposure to AP extracts. (a) Cells were
treated with 0, 25, 50, 100, 150 or 200μg/mL of AP extracts for 24h. (b) Cells were treated with 150μg/mL of AP extracts for 0, 4, 8, 12, 18
or 24 h. Protein (50μg) from each sample was resolved on 8–15% SDS-PAGE and western blotting was performed. β- a c t i nw a su s e da sa
control. Relative changes in protein bands were measured using densitometric analysis.Typical results from three independent experiments
are shown.
the proliferating cells in the control group, while the mitosis-
positive cells decreased in sections from the treated animals
(Figure 7(b)). These results demonstrated AP extract-related
antitumor activity in nude mice bearing KB epidermoid
carcinoma xenografts.
3.6.Induction ofApoptoticDNAFragmentationbyAPExtracts
in Xenograft Tumors. The eﬀect of AP extracts on tumor
growth (apoptosis) in the KB xenograft mice was also exam-
ined using the TUNEL assay on the tumor sections. Figures
8(a) and 8(b) show that there were more TUNEL-positive
cells in tumors from AP extract-treated animals, relative to
that of the untreated controls. These results demonstrated
that AP extract treatment was associated with decreased
proliferation and increased apoptosis in the study animals.
Analysis of our data suggests that AP extracts promoted
antitumor activity in nude mice bearing KB epidermoid
carcinoma xenografts.
4.Discussion
Herbal medicine is one of the most ancient forms of health
care known to humankind and it has been used in many cul-
tures throughout history. Several studies have demonstrated6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Western blot analysisofMMP-9, u-PA, u-PAR, TIMP-1 and PAI-1 protein levels in KB cells after exposure to AP extracts. (a) Cells
were treated with 0, 25,50, 100, 150 or 200μg/mL of AP extracts for 24 h. (b) Cells were treated with 150μg/mL of AP extracts for 0, 4, 8, 12,
18 or 24 h. Protein (50μg) from each sample was resolved on 8–15% SDS-PAGE and western blotting was performed. β- a c t i nw a su s e da sa
control. Relative changes in protein bands were measured using densitometric analysis.Typical results from three independent experiments
are shown.
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Figure 5: Eﬀects of AP extracts on the activities of MMP-9. KB
cells were treated with 0, 25, 50, 100, 150 or 200μg/mL of AP
extracts for 24 h and then subjected to gelatin zymography to
analyze the activities of MMP-9. Relative changes in protein bands
were measured using densitometric analysis. Typical results from
three independent experiments are shown. Results are presented as
mean ±SD ofthree assays. ∗Signiﬁcantdiﬀerence in comparisonto
control group (P < .05).
anticancer potential for extracts from a number of herbal
m e d i c i n e so rm i x t u r e sin vitro or in vivo.T y p i c a l l y ,h e r b a l
medicines emphasize the use of whole extracts from a plant
mix or from complex formulations [25]. Anticancer agents
may alter regulation of the cell cycle machinery, resulting in
cellulararrest atdiﬀerentphases ofthecellcycleand,thereby,
reducing the growth and proliferation of, and even inducing
apoptosis in, cancerous cells. The present research docu-
ments a parallel study showing the eﬀect of AP extract treat-
ment in vivo in a human tumor xenograft in nude mice and
in vitro in a cell culture model involving human squamous
carcinoma KB cells. From those results, we determined that
APextractarrestsKBcellsattheG2/Mphaseby(i)inhibiting
protein levels of cyclin A and cyclin B1, (ii) decreasing Cdc2
and Cdc25C levels, (iii) increasing p21/WAF1, Wee1, p53
and p-p53 levels, (iv) decreasing MMP-9 and u-PA, and
increasing their endogenous inhibitors, TIMP-1 and PAI-1.
Moreover, our previous investigation has demonstrated that
AP extracts exhibit an antiproliferative eﬀect by induction
of apoptosis in KB cells [19]. Studies in the past decade
have shown that concurrent chemotherapy programs have
the potential to improve the overall survival of patients
with squamous cell carcinoma. Interestingly, A. pricei has
been found to have lesser cytotoxicity towards the normal
human ﬁbroblast (HGF) cells [19]. These results suggest
that A. pricei m a yb eu s e f u lf o rt h ep r e v e n t i o na n d / o r
treatment of patients with cancer. Furthermore, in vivo
toxicity was also examined superﬁcially from body weight
changes and histological studies of vital organs (data not
shown). There appeared to be no signs of signiﬁcant toxicity
at A. pricei e x p o s u r e so f1 0m g / k g .T h i sl i k e l yi n d i c a t e st h a t
there are no side eﬀects at these doses. Investigation of
the nontoxic characteristics of A. pricei in rats is necessary,
which may increase its potential for application in food and
drug products. Future studies should test whether there isEvidence-Based Complementary and Alternative Medicine 7
27 24 21 18 15 12 9 6 3 0
Days treated with drugs
Control
AP extracts
18
19
20
21
22
B
o
d
y
w
e
i
g
h
t
(
g
)
(a)
∗ ∗
∗
∗
27 24 21 18 15 12 9 6 3 0
Days treated with drugs
Control
AP extracts
0
200
400
600
800
1000
1200
1400
T
u
m
o
r
v
o
l
u
m
e
(
m
m
3
)
(b)
Figure 6: Time-course eﬀect of AP extracts on growth of KB xenografted nude mice was evaluated by measurements of body weight (a) and
tumorvolume(b) every 3 days. KB cells were implantedsubcutaneously into theﬂanksofnude miceonDay 0, theanimalswere then treated
with 10mg/kg of AP extracts or were untreated (control). Results are presented as mean ± SE (n = 6). ∗Signiﬁcantdiﬀerence in comparison
to control group (P < .05).
an optimal/eﬀective dose for A. pricei exposure. Summary
of our data suggests that treatment with AP extracts could
be eﬀective in suppressing the proliferation of KB cells as
shown by growth inhibition, cell cycle arrest, and apoptosis
induction in vivo or in vitro.
Disturbance of the cancer cell cycle is one of the thera-
peutic targets for development of new anticancer drugs [26].
Severalstudieshavereportedthatvariouscytotoxicdrugscan
induceG2/Mphasearrest [27].Theresultsofcellcycleanaly-
sis in the present study, as evaluated by ﬂow cytometry, show
that the AP extract treatment had a profound eﬀect on cell
cycle control, with squamous carcinoma cells accumulating
in the G2/M phase. This cell cycle blockade was associated
with reductions in cyclin A, cyclin B1, Cdc2 and Cdc25C,
and increased CDK inhibitor p21/WAF1, Weel, p53 and p-
p53. Eukaryotic cell cycle progression involves the sequential
activation of CDK, whose activation is dependent upon
association with cyclins.AmongCDKsthatregulatecellcycle
progression, CDK2 and Cdc2 kinases are primarily activated
in association with cyclinAand cyclinB1during progression
of the G2/M phase [28, 29]. The phosphorylation of Tyr15
of Cdc2 suppresses activity of Cdc2/cyclin A and B1 kinase
complex. Dephosphorylation of Tyr15 of Cdc2 is catalyzed
by Cdc25C phosphatase, and this reaction is believed to
be the rate-limiting step for entry into mitosis [30]. P53
could act as a sensor for DNA damage that could arrest
the cell cycle for DNA repair or upregulate pro-apoptotic
factors resulting in increased susceptibility to apoptosis.
Following DNA damage, the CDK inhibitor p21/WAF1 is
expressed in p53-dependent or p53-independent manner
[31]. P21/WAF1 may help to maintain G2/M cell cycle
arrest by inactivating cyclin B1/Cdc2 complex, disrupting
theinteractionbetweenproliferatingcellnuclearantigenand
Cdc25C [31]. The results imply that the expression of cyclin
A, cyclinB, Cdc2and Cdc25Care down-regulated, and CDK
inhibitors p21/WAF1, Weel, p53 and p-p53 are increased in
AP extract-treated KB cells, which corroborates G2/M block.
Analysis of our data suggests that the observed inhibition of
proliferationofKBcellsassociated with APextract treatment
couldbe theresult ofcell cyclearrest during the G2/M phase.
Metastasis is the spread of cancer cells from the primary
tumor to the new metastatic sites via blood or lymph vessels
[32]. MMPs and u-PA, which are secreted by invasive cancer
cells, play important roles in cancer cell invasion and metas-
tasis because tumor cells must cross type IV collagen-rich
basement membrane of vessel walls to spread to other sites
during a period of cancer metastasis [32]. In vivo evidence
from the chicken chorionallantoic membrane assay showed
thatMMP-9 and u-PA are interdependentin tumorinvasion,
which also showed that invasion was dependent on both
MMP-9 and u-PA, because in the absence of MMP-9 and
u-PA, tumor cells showed only low levels of invasion [33].
Therefore, inhibition of invasion mediated by MMP-9 and
u-PA may be a key feature for the prevention of cancer
metastasis. Physiological activities of MMPs and u-PA were
greatly related to that of TIMP and PAI, respectively, their
speciﬁc endogenous inhibitors. Furthermore, TIMPs play a
key role in determining the proteolytic activity of tumor
tissues by regulating the activity of MMPs. Accordingly,
several studies demonstrated correlation between high inva-
siveness and decreased MMP-2 expression [34, 35]. Con-
versely, the anti-invasive action of several anticarcinogenic
substances is associated with elevated MMP-1 levels [36].
PAIs (serine protease inhibitors) regulate uPA and tissue
plasminogen activator (tPA) to control plasmin generation.
PAI is implicated as a mediator of invasion and metastasis
in several tumor types [37]. There is increasing evidence
for PAI in cancer metastasis independent of its protease8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: In vivo inhibition of KB xenograft proliferation by AP extracts. (a) Nude mice were untreated (control) or treated with 10mg/kg
of AP extracts. On the 27th day after tumor implantation, the animals were sacriﬁced and the tumors were removed. (b) The control KB
xenograft tumor and the KB xenograft tumors after AP extract treatment were sectioned and stained with hematoxylin and eosin, examined
with light microscopy. Arrows indicate mitosis-positive cells. Typical results from three independent experiments are shown.
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Figure8:ImmunohistochemicalstainingofapoptoticDNAfragmentationinKBxenografttumors.Insituapoptosisdetection usingTUNEL
staining in tumor sections from control animals (a) and experimental analogs treated with AP extracts (10mg/kg) (b). Arrow indicates
apoptotic-positive cells. Typical results from three independent experiments are shown.
inhibitory activity, such as tumor cell motility, cell and anti-
cell adhesion, pro- and anti-angiogenesis, and prevention of
apoptosis [37]. In cervical cancer, increased levels of uPA
and PAI-1 proteins were detected in cervical tumor extracts
but not in normal tissue extracts [38]a n da r el i n k e dt o
poor prognosis [39]. In this study, we revealed that AP
extracts decreased protein levels of tumor metastasis-related
proteins such as MMP-9 and u-PA in KB cells. Meanwhile,
their endogenous inhibitors, which are TIMP-1 and PAI-
1, were increased in KB cells. It has been shown that KB
cells exhibited a reduced motility and also reﬂected fewer
invasions without altering the MMP status [40]. Therefore,
the inhibition of KB cell migration and invasion by AP ex-
tracts was not examined in this study.
Our previous investigation demonstrated that AP extract
exhibits an antiproliferative eﬀect by induction of apop-
tosis that is associated with loss of cell viability, morpho-
logic change, internucleosomal DNA fragmentation, sub-
G1 phase accumulation, loss of mitochondrial membrane
potential (ΔΨm), cytochrome c translocation, caspase-3 and
-9,activation,polyadenosinediphosphate-ribosepolymerase
(PARP) degradation, dysregulation of Bcl-2 and Bax, andEvidence-Based Complementary and Alternative Medicine 9
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Figure 9: Proposed diagrams of AP extracts-induced apoptosis, G2/M arrest and metastasis inhibition in KB cells.
generation of reactive oxygen species (ROS) in KB cells
[19].Apoptosisisanimportant homeostaticmechanism that
balancescelldivisionandcelldeathandmaintains theappro-
priate number of cells in the body. Disturbances of apoptosis
in cancer cells have been studied in detail, and induction of
apoptosis in these cells is one of the strategies for anticancer
drug development [41]. Furthermore, tumor inhibition by
AP extract was also observed in the nude mice xenograft
m o d e li nt h i ss t u d y .B o t hi n c i d e n c ea n dm e a nt u m o r
volume were signiﬁcantly reduced by AP extract treatment.
Immunohistochemical staining revealed increased apoptosis
(TUNEL assay) in tumors from the AP extract-treated
animals. Analysis of our data suggests that AP extracts could
induce apoptotic cell death in human squamous carcinoma
KB cells both in vitro and in vivo.
Natural products, including plants, provide rich resour-
ces for anticancer drug discovery [42–44]. As the diﬀerent
components in a given herb may have synergistic activities
orbuﬀertoxiceﬀects,mixturesorextractsoftheseherbsmay
oﬀer greater therapeutic or preventive activity when used in
combination [45]. In our study, a number of com-pounds,
including desmethoxyyangonin, cardamonin, and ﬂavoka-
wain B were isolated from ethanol extracts of the A. pricei
root [10]. These results imply that desmethoxyyangonin,
cardamonin and ﬂavokawain Bcouldact aspotentialchemo-
preventive agents with respect to inhibition of the prolif-
eration (growth) of human squamous carcinoma KB cells,
throughtheinductionofcellcyclearrest/apoptosis in vitro or
in vivo. Further studies to identify the active constituents in
A. pricei rhizome extracts leading to antitumor eﬀects would
be most important for future work.
Based on the outcome of our studies, the mechanisms
by which AP extracts-induced apoptosis, G2/M arrest and
metastasis inhibition in KB cells are summarized in Figure 9.
Our data suggest that extracts of A. pricei merit investigation
as antitumor agents for treatment of human squamous
carcinoma KB cells. These data impart important knowledge
in the development of food and drug products for human
use. Further in vivo studies using other animal models and
humans are necessary to elaborate and exploit this nascent
promise.
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